Filtered By:
Drug: Phenytoin
This page shows you your search results in order of date. This is page number 10.
Order by Relevance | Date
Total 177 results found since Jan 2013.
First case of MELAS syndrome presenting with local brain edema requiring decompressive craniectomy
CONCLUSION: If the diagnosis and treatment are delayed, MELAS syndrome can cause serious brain edema, which may ultimately require decompressive craniectomy.PMID:34664704 | DOI:10.5137/1019-5149.JTN.34196-21.4
Source: Turkish Neurosurgery - October 19, 2021 Category: Neurosurgery Authors: Osman Yesilbas Esma Sengenc Melike Ersoy Olbak Derya Bako Oznur G ökce Nizam Mehmet Hakan Seyithanoglu Davut Pehlivan Serdar Ceylaner Dilara Icagasioglu Kursad Aydin Source Type: research
Association between Use of Pharmacokinetic-Interacting Drugs and Effectiveness and Safety of Direct Acting Oral Anticoagulants: Nested Case-Control Study
Clin Pharmacol Ther. 2021 Jul 19. doi: 10.1002/cpt.2369. Online ahead of print.ABSTRACTConcomitant use of direct oral anticoagulants (DOACs) and medications with inhibition/induction effect on P-gp/CYP3A might increase risk of bleeding/treatment failure, respectively. We designed a nested case-control study within a Clalit cohort of atrial fibrillation (AF) patients and a cohort of venous thromboembolic patients, new users of a DOAC (1.1.2010-24.8.2020). Propensity scores were constructed from demographic, clinical and medications at cohort entry. Each case of: 1) serious bleeding event; 2) stroke/systemic emboli (SE) in A...
Source: Clinical Pharmacology and Therapeutics - July 21, 2021 Category: Drugs & Pharmacology Authors: Naomi Gronich Nilli Stein Mordehcai Muszkat Source Type: research
Janssen Announces U.S. FDA Approval of PONVORY ™ (ponesimod), an Oral Treatment for Adults with Relapsing Multiple Sclerosis Proven Superior to Aubagio® (teriflunomide) in Reducing Annual Relapses and Brain Lesions
TITUSVILLE, N.J. – (March 19, 2021) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) approved PONVORY™ (ponesimod), a once-daily oral selective sphingosine-1-phosphate receptor 1 (S1P1) modulator, to treat adults with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.1,2,3 PONVORY™ offers MS patients superior efficacy in reducing annualized relapse rates compared to an established oral therapy and a proven safety profile backed by ove...
Source: Johnson and Johnson - March 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Concomitant Use of Direct Oral Anticoagulants and Antiepileptic Drugs: A Prospective Cohort Study in Patients with Atrial Fibrillation
ConclusionIn this cohort, patients with non-valvular AF treated with DOACs and antiepileptic drugs appear to have a relatively high rate of thromboembolic events.
Source: Clinical Drug Investigation - December 7, 2020 Category: Drugs & Pharmacology Source Type: research
Nonconvulsive Status Epilepticus With Neuropsychological Symptoms: Two Case Reports
We report two such cases. Case 1, a 62-year-old man with a history of a subcortical hemorrhage in the right lateral temporal lobe and a brain infarct in the left medial temporo-occipital lobes, suddenly developed left unilateral spatial neglect and visual object agnosia. Diffusion-weighted imaging indicated status epilepticus, not stroke. His deficits resolved immediately after treatment with diazepam and phenytoin sodium. Case 2, a 61-year-old man with a history of brain infarcts in the right lateral temporal and left medial temporo-occipital lobes, suddenly developed global aphasia and cortical deafness. An MRI revealed ...
Source: Cognitive and Behavioral Neurology - December 1, 2020 Category: Neurology Tags: Case Reports Source Type: research
Janssen Highlights Continued Commitment to Cardiovascular & Metabolic Healthcare Solutions with Late-Breaking Data at the First Fully Virtual American College of Cardiology Scientific Session
RARITAN, N.J., March 20, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that it will unveil late-breaking data from its leading cardiovascular and metabolism portfolio during the virtual American College of Cardiology’s 69th Annual Scientific Session together with the World Congress of Cardiology (ACC.20/WCC) on March 28-30, 2020. Notably, four late-breaking abstracts for XARELTO® (rivaroxaban) will be presented, including data from the Phase 3 VOYAGER PAD study in patients with symptomatic peripheral artery disease (PAD) after lower-extremity revascularization.Click to Tweet: Jan...
Source: Johnson and Johnson - March 20, 2020 Category: Pharmaceuticals Source Type: news
The Prevalence and Factors Associated with Antiepileptic Drug Use in US Nursing Home Residents
ConclusionsAED use was common in nursing homes, with gabapentin most commonly used (presumably for pain). That multiple comorbidities were associated with AED use underscores the need for future studies to investigate the safety and effectiveness of AED use in nursing home residents.
Source: Drugs and Aging - December 15, 2019 Category: Geriatrics Source Type: research
Weight! Weight! … Don’t Tell Me!
Weight-based, lifesaving medications are commonly used in hospitals and routinely used in emergency departments.1 Many weight-based medications are listed in the Institute for Safe Medication Practices (ISMP) high-alert medication list. According to ISMP, “high-alert medications are drugs that bear a heightened risk of causing significant patient harm when they are used in error.”2 These frequently used medications include anticoagulants (eg, heparin and enoxaparin), antibiotics for septic shock (eg, vancomycin and tobramycin), fibrinolytic agent s for stroke (eg, alteplase), and antiepileptic drugs (eg, phenytoin and fosphenytoin).
Source: Journal of Emergency Nursing: JEN - August 22, 2019 Category: Nursing Authors: Avani Bhalodia, Mona Hammam, Susan F. Paparella Tags: Danger Zone Source Type: research
Protective Role of Levetiracetam Against Cognitive Impairment And Brain White Matter Damage in Mouse prolonged Cerebral Hypoperfusion
Publication date: Available online 11 July 2019Source: NeuroscienceAuthor(s): Toshiki Inaba, Nobukazu Miyamoto, Kenichiro Hira, Yuji Ueno, Kazuo Yamashiro, Masao Watanabe, Yoshiaki Shimada, Nobutaka Hattori, Takao UrabeAbstractWhite matter lesions due to cerebral hypoperfusion may be an important pathophysiology in vascular dementia and stroke, although the inherent mechanisms remain to be fully elucidated. The present study, using a mouse model of chronic cerebral hypoperfusion, examined the white matter protective effects of levetiracetam, an anticonvulsant, via the signaling cascade from the activation of cAMP-responsiv...
Source: Neuroscience - July 12, 2019 Category: Neuroscience Source Type: research
Increased risk of stroke and myocardial infarction in patients with epilepsy: A systematic review of population-based cohort studies
ConclusionsPatients with epilepsy are at higher risk of subsequent stroke and MI in comparison with subjects without epilepsy. Although individual AEDs may carry different risks of cardio- and cerebrovascular disease, the clinical relevance of the metabolic effects of the enzyme-inducing AEDs is still uncertain.This article is part of the Special Issue “Seizures & Stroke
Source: Epilepsy and Behavior - June 8, 2019 Category: Neurology Source Type: research
Increased risk of stroke and myocardial infarction in patients with epilepsy: A systematic review of population-based cohort studies.
CONCLUSIONS: Patients with epilepsy are at higher risk of subsequent stroke and MI in comparison with subjects without epilepsy. Although individual AEDs may carry different risks of cardio- and cerebrovascular disease, the clinical relevance of the metabolic effects of the enzyme-inducing AEDs is still uncertain. This article is part of the Special Issue "Seizures & Stroke.
PMID: 31182394 [PubMed - as supplied by publisher]
Source: Epilepsy and Behaviour - June 6, 2019 Category: Neurology Authors: Brigo F, Lochner P, Nardone R, Manganotti P, Lattanzi S Tags: Epilepsy Behav Source Type: research
